Meeting
2023 ASCO Annual Meeting
A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors.
Authors
Jordi Rodon Ahnert
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Jordi Rodon Ahnert , Joshua James Gruber , Melinda L. Telli , Monica M. Mita , Alain C. Mita , Joseph W. Kim , Miguel Angel Villalona-Calero , Meera Patel , Shalini S. Yadav , Padmanee Sharma , Tom Haber , Jessica Lauren Symons , Qihui Seet , Bhushan Dharmadhikari , Dipti Thakkar , Kon Yew Kwek , Leah DiMascio , Eric Keith Rowinsky , Piers Ingram , Jerome Douglas Boyd-Kirkup
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Antibodies
Clinical Trial Registration Number
NCT05082610
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS2664)
DOI
10.1200/JCO.2023.41.16_suppl.TPS2664
Abstract #
TPS2664
Poster Bd #
505b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase 1 first-in-human dose finding/randomized phase 2 study of IMM60 and pembrolizumab (PEM) in advanced melanoma and non–small cell lung cancer (NSCLC; IMP-MEL).
First Author: Nicholas Coupe
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors.
First Author: Iwona A. Lugowska
Poster
2023 ASCO Annual Meeting
A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).
First Author: Mohamed Shanshal
Poster
2023 ASCO Annual Meeting
IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC).
First Author: Nicholas Coupe